Preventing variceal bleeding in liver cancer patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study compares two ways to prevent bleeding from enlarged veins in the esophagus (varices) in people with liver cancer and cirrhosis. One method uses a medication called carvedilol alone, while the other combines carvedilol with a procedure called band ligation, which ties off the veins to prevent bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have cirrhosis (scarring of the liver) and liver cancer.
- You have high-risk varices (enlarged veins in the esophagus that are likely to bleed).
- You have not had variceal bleeding in the past.
- You have not had band ligation or sclerotherapy (injections) for varices in the last 3 months.
- You are not scheduled for a liver transplant within the next 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tying off high-risk veins in the esophagus before starting a common liver cancer treatment can prevent bleeding. It is for people with liver cancer that has spread but who have never had cancer treatment before.
This study compares two ways to stop variceal bleeding (bleeding from swollen veins in the esophagus or stomach) from coming back in people with liver cancer. It tests whether an ultrasound-guided technique during endoscopy can reduce repeat bleeding compared with standard endoscopy methods.
This trial tests whether carvedilol can prevent the first development of swollen veins (varices) in the esophagus in people with cirrhosis who do not have them yet. It may help lower the risk of future bleeding from those veins.
This study tests whether adding a second drug (midodrine) to the standard drug (carvedilol) is better at preventing another bleeding episode from varices in people with cirrhosis. It aims to reduce the risk of early re-bleeding and improve outcomes.
This trial tests whether adding metformin to carvedilol (a standard drug) lowers liver pressure more than carvedilol alone in people with cirrhosis who have had variceal bleeding. The goal is to prevent future bleeding.
This trial compares two treatments (banding or a medication called carvedilol) to prevent the first episode of bleeding from enlarged veins in the esophagus in people with liver cancer. The goal is to find which approach is safer and more effective.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.